Pemetrexed Maintenance Therapy Following Bevacizumab-Containing First-Line Chemotherapy in Advanced Malignant Pleural Mesothelioma: A Case Report and Literatures Review.
Pemetrexed Maintenance Therapy Following Bevacizumab-Containing First-Line Chemotherapy in Advanced Malignant Pleural Mesothelioma: A Case Report and Literatures Review.
复制标题
晚期恶性胸膜间皮瘤含贝伐单抗一线化疗后的培美曲塞维持治疗
DOI：
10.1097/md.0000000000003351
复制
发表时间：
2016-04
期刊：
影响因子：
1.6
通讯作者：
Meng X
中科院分区：
文献类型：
--
作者：
Jing XQ;Zhou L;Sun XD;Yu JM;Meng X
恶性胸膜间皮瘤（MPM）是一种致死性疾病，预后差。顺铂和培美曲塞联合治疗已被确认为不可手术MPM的标准治疗。数据显示，一线治疗后采用培美曲塞维持治疗（PMT）似乎非常有希望。我们描述了一名57岁男性被诊断为晚期MPM。我们在一线顺铂为基础的含贝伐珠单抗化疗后用PMT治疗该患者，6个疗程的PMT后残留肿瘤消失。本例患者肿瘤完全消失，无进展生存期（PFS）14个月，表明贝伐珠单抗联合一线化疗是可行的，PMT治疗晚期MPM是有希望的。我们还需要对晚期MPM患者的一线治疗、持续维持治疗、转换维持治疗和二线治疗的文献进行综述。
AbstractMalignant pleural mesothelioma (MPM) is a lethal disease with poor prognosis. The combination of cisplatin and pemetrexed has been confirmed as the standard of care for nonoperable MPM. Data have shown that the adoption of pemetrexed maintenance therapy (PMT) following first-line treatment appears extremely promising.We describe a 57-year-old man diagnosed as advanced MPM. We treated this patient with PMT after first-line cisplatin-based bevacizumab-containing chemotherapy and residual tumor disappeared after 6 course of PMT. A perfect response and a long progression-free survival (PFS) were reached with tumor mass disappearing and 14 months duration of PFS.This case suggests that adding bevacizumab to standard first-line chemotherapy is feasible and that PMT could be promising and useful for treating advanced MPM. We further entail a review of the literature on the first-line treatment, continuation maintenance therapy, switch maintenance therapy, and second-line treatment of patients with advanced MPM.